Table 1. Open in new tab Baseline...

Baseline characteristics

N = 221

Age^a

Median [IQR]

38.2 [29.3–52.2]

Sex, male

N [%]

88 [39.8]

Body mass index^a

Mean [SD]

23.7 [5.0]

Disease duration, years

Median [IQR]

12.3 [7.5–19.3]

Follow-up duration, years

Median [IQR]

52.0 [49.3–58.4]

Disease location^b

Ileum

N [%]

68 [30.8]

Colon

N [%]

76 [34.4]

Ileocolonic

N [%]

77 [34.8]

Upper GI tract involvement^b

N [%]

12 [5.4]

Disease behaviour^b

Inflammatory disease

N [%]

113 [51.1]

Stricturing disease

N [%]

63 [28.5]

Penetrating disease

N [%]

40 [18.1]

Unknown

N [%]

5 [2.3]

Peri-anal disease^b

N [%]

37 [16.7]

Prior intestinal resections

N [%]

137 [62.0]

Prior peri-anal interventions

N [%]

47 [21.3]

Prior anti-TNF therapy

≥1

N [%]

218 [98.6]

≥2

N [%]

162 [73.3]

N [%]

11 [5.0]

Prior vedolizumab

N [%]

103 [46.6]

Prior anti-TNF and vedolizumab

N [%]

102 [46.2]

Disease activity^a

Harvey Bradshaw Index

Median [IQR]

7 [4–11]

CRP, mg/L

Median [IQR]

9 [3–20]

Faecal calprotectin, µg/g

Median [IQR]

699 [211–1536]

Concomitant medication^a

Corticosteroids

N [%]

35 [15.8]

Corticosteroids range

mg [IQR]

20 [19–30]

Immunosuppressants

N [%]

44 [19.9]

Both corticosteroids and immunosuppressants

N [%]

12 [5.4]

Corticosteroids range

mg [IQR]

25 [13–38]

Table 1.

Open in new tab

Baseline patient characteristics

Baseline characteristics		N = 221
Age^a	Median [IQR]	38.2 [29.3–52.2]
Sex, male	N [%]	88 [39.8]
Body mass index^a	Mean [SD]	23.7 [5.0]
Disease duration, years	Median [IQR]	12.3 [7.5–19.3]
Follow-up duration, years	Median [IQR]	52.0 [49.3–58.4]
Disease location^b
Ileum	N [%]	68 [30.8]
Colon	N [%]	76 [34.4]
Ileocolonic	N [%]	77 [34.8]
Upper GI tract involvement^b	N [%]	12 [5.4]
Disease behaviour^b
Inflammatory disease	N [%]	113 [51.1]
Stricturing disease	N [%]	63 [28.5]
Penetrating disease	N [%]	40 [18.1]
Unknown	N [%]	5 [2.3]
Peri-anal disease^b	N [%]	37 [16.7]
Prior intestinal resections	N [%]	137 [62.0]
Prior peri-anal interventions	N [%]	47 [21.3]
Prior anti-TNF therapy
≥1	N [%]	218 [98.6]
≥2	N [%]	162 [73.3]
3	N [%]	11 [5.0]
Prior vedolizumab	N [%]	103 [46.6]
Prior anti-TNF and vedolizumab	N [%]	102 [46.2]
Disease activity^a
Harvey Bradshaw Index	Median [IQR]	7 [4–11]
CRP, mg/L	Median [IQR]	9 [3–20]
Faecal calprotectin, µg/g	Median [IQR]	699 [211–1536]
Concomitant medication^a
Corticosteroids	N [%]	35 [15.8]
Corticosteroids range	mg [IQR]	20 [19–30]
Immunosuppressants	N [%]	44 [19.9]
Both corticosteroids and immunosuppressants	N [%]	12 [5.4]
Corticosteroids range	mg [IQR]	25 [13–38]

Baseline characteristics		N = 221
Age^a	Median [IQR]	38.2 [29.3–52.2]
Sex, male	N [%]	88 [39.8]
Body mass index^a	Mean [SD]	23.7 [5.0]
Disease duration, years	Median [IQR]	12.3 [7.5–19.3]
Follow-up duration, years	Median [IQR]	52.0 [49.3–58.4]
Disease location^b
Ileum	N [%]	68 [30.8]
Colon	N [%]	76 [34.4]
Ileocolonic	N [%]	77 [34.8]
Upper GI tract involvement^b	N [%]	12 [5.4]
Disease behaviour^b
Inflammatory disease	N [%]	113 [51.1]
Stricturing disease	N [%]	63 [28.5]
Penetrating disease	N [%]	40 [18.1]
Unknown	N [%]	5 [2.3]
Peri-anal disease^b	N [%]	37 [16.7]
Prior intestinal resections	N [%]	137 [62.0]
Prior peri-anal interventions	N [%]	47 [21.3]
Prior anti-TNF therapy
≥1	N [%]	218 [98.6]
≥2	N [%]	162 [73.3]
3	N [%]	11 [5.0]
Prior vedolizumab	N [%]	103 [46.6]
Prior anti-TNF and vedolizumab	N [%]	102 [46.2]
Disease activity^a
Harvey Bradshaw Index	Median [IQR]	7 [4–11]
CRP, mg/L	Median [IQR]	9 [3–20]
Faecal calprotectin, µg/g	Median [IQR]	699 [211–1536]
Concomitant medication^a
Corticosteroids	N [%]	35 [15.8]
Corticosteroids range	mg [IQR]	20 [19–30]
Immunosuppressants	N [%]	44 [19.9]
Both corticosteroids and immunosuppressants	N [%]	12 [5.4]
Corticosteroids range	mg [IQR]	25 [13–38]

IQR, interquartile range; SD, standard deviation; GI, gastrointestinal; anti-TNF: anti-tumour necrosis factor; CRP, C-reactive protein.

^aAt inclusion.

^bMaximum extent until inclusion.

This Feature Is Available To Subscribers Only